Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Oct 03, 2018 3:16pm

115 Views

Post# 28739736

RE:RE:RE:RE:RE:RE:Tomorrow

This doc is the agenda for the public meeting that considered Trogarzo, in it they say the final decision is expected late November.

https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/Downloads/2018-05-15-HCPCS-Public-Meeting-Agenda.pdf

mattw1100 wrote: SPCEO1 are you still holding your patient number at I think it was around 700/750 by end of 2018?

Anyone have insights on J-Code and the potential to help Trogarzo? This is not something I have seen come up before?

By the end of the year, Trogarzo injectable treatment should also benefit from the US J-Code program that facilitates reimbursement for infusion therapy, says Steadman.